
Chapter 54 SKIN DISEASES382
24. What are the divisions of the classes of topical corticosteroids? On which
areas of the skin are they appropriately applied?
n
Low-potency topical corticosteroids (class 6 or 7 topical steroids, such as 1% and 2.5%
hydrocortisone, 0.05% desonide) are appropriate to use on the face, axillae, groin, breasts,
and genitalia, where the skin is thinner and more prone to cutaneous side effects.
n
Moderate-potency topical corticosteroids (class 4 or 5 topical steroids, such as 0.025%
fluocinolone, 0.1% triamcinolone, 0.2% hydrocortisone valerate) are useful on the neck and
body, avoiding the more sensitive areas mentioned previously. This class is given most
appropriately as first-line therapy for skin conditions diagnosed in the ED.
n
High-potency topical corticosteroids (class 2 or 3 topical steroids, such as 0.05%
fluocinonide, 0.1% halcinonide, 0.25% desoximetasone) should not be applied to the face,
breasts, genitalia, axillae, or groin. Topicals in this class are more likely to produce
cutaneous side effects if used diffusely or for long periods (.2 weeks). This class should
be prescribed only if moderate-potency topical corticosteroids have not been effective or if
the condition is limited to the particularly thick skin of the palms and soles.
n
Superpotent topical corticosteroids (class 1 topical steroids, such as 0.05% clobetasol,
0.05% betamethasone dipropionate in optimized vehicle, 0.05% halobetasol, 0.05%
diflorasone) are usually reserved for chronic, recalcitrant conditions, often of the palms and
soles. The risk of cutaneous side effects is greatest with this class, and this class of steroid
should be dispensed in a continuity-of-care rather than an ED setting.
25. Does the vehicle of the topical corticosteroid affect potency?
Yes. The same corticosteroid may be significantly more or less potent, depending on the
vehicle. In general, ointments are most potent, followed by gels, emollients, creams, lotions,
solutions, and sprays.
BIBLIOGRAPHY
1. Dyer JA: Childhood Viral Exanthems. Pediatr Ann 36(1):21–29, 2007.
2. French LE, Prins C: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In
Bolognia JL, Jorizzo JL, Rapini RP, editors: Dermatology ed 2, London, 2008, Mosby, pp 287–300.
3. Frigas E, Park MA: Acute urticaria and angioedema: diagnostic and treatment considerations. Am J Clin
Dermatol 10(4):239–250, 2009.
4. Ghislain PD, Roujeau JC: Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal
necrolysis and hypersensitivity syndrome. Dermatol Online J 8(1):5, 2002.
5. May TJ, Safranek S: Clinical inquiries. When should you suspect community-acquired MRSA? How should you
treat it? J Fam Pract 58(5):276, 278, 2009.
6. Patel M: Community acquired methicillin-resistant Staphylococcus aureus: epidemiology, recognition, and
management. Drugs 69(6):693–716, 2009.
7. Revuz J, Valeyrie-Allanore L: Drug reactions. In: Bolognia JL, Jorizzo JL, Rapini RP, editors: Dermatology ed 2,
London, 2008, Mosby, pp 301–320.
8. Roujeau JC, Kelly JP, Naldi L, et al: Medication use and the risk of Stevens-Johnson syndrome or toxic
epidermal necrolysis. N Engl J Med 333:1600–1607, 1995.
9. Sams HH, Dunnick CA, Smith ML, et al: Necrotic arachnidism. J Am Acad Dermatol 44:561–573, 2001.
WEBSITE
www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf